These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 18424820)

  • 21. [Drugs inhibiting parathyroid hormone (PTH) secretion by control of the calcium receptor (calcimimetics)--effect on the set point of calcium-regulated PTH secretion].
    Nagano N
    Clin Calcium; 2005 Jan; 15(1):71-8. PubMed ID: 15632475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Calcimimetics, mechanisms of action and therapeutic applications].
    Ureña P; Legoupil N; de Vernejoul MC
    Presse Med; 2005 Sep; 34(15):1095-100. PubMed ID: 16334889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG
    N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional proteins involved in regulation of intracellular Ca(2+) for drug development: the extracellular calcium receptor and an innovative medical approach to control secondary hyperparathyroidism by calcimimetics.
    Nagano N; Nemeth EF
    J Pharmacol Sci; 2005 Mar; 97(3):355-60. PubMed ID: 15781990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How do calcimimetics fit into the management of parathyroid hormone, calcium, and phosphate disturbances in dialysis patients?
    Shahapuni I; Mansour J; Harbouche L; Maouad B; Benyahia M; Rahmouni K; Oprisiu R; Bonne JF; Monge M; El Esper N; Presne C; Moriniere P; Choukroun G; Fournier A
    Semin Dial; 2005; 18(3):226-38. PubMed ID: 15934970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New insights into the role of calcium-sensing receptor activation.
    Cozzolino M; Mazzaferro S; Messa P
    J Nephrol; 2011; 24 Suppl 18():S38-41. PubMed ID: 21623581
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The dependency of calcium set point on basal plasma calcium in dialysis patients: a better explanation for the discrepancies regarding its link with PTH secretion than methodological differences.
    Hardy-Yverneau P; Shenouda M; Moriniere P; Legallais C; Brazier M; Achard J; Fournier A
    Clin Nephrol; 1998 Oct; 50(4):236-46. PubMed ID: 9799069
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.
    Colloton M; Shatzen E; Miller G; Stehman-Breen C; Wada M; Lacey D; Martin D
    Kidney Int; 2005 Feb; 67(2):467-76. PubMed ID: 15673294
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypercalcemia due to resistant hyperparathyroidism in renal transplant patients treated with the calcimimetic agent cinacalcet.
    Apostolou T; Kollia K; Damianou L; Kaitsioti H; Kotsiev V; Dracopoulos S; Vougas V; Hadjiconstantinou V
    Transplant Proc; 2006 Dec; 38(10):3514-6. PubMed ID: 17175318
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High-normal calcium (1.35 mmol/l) dialysate in patients on CAPD: efficient and safe long-term control of plasma calcium, phosphate, and parathyroid hormone.
    Bro S; Brandi L; Olgaard K
    Nephrol Dial Transplant; 1996 Aug; 11(8):1586-91. PubMed ID: 8856216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients.
    Fukagawa M; Yumita S; Akizawa T; Uchida E; Tsukamoto Y; Iwasaki M; Koshikawa S;
    Nephrol Dial Transplant; 2008 Jan; 23(1):328-35. PubMed ID: 17717030
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cinacalcet HCl: a calcimimetic agent for the management of primary and secondary hyperparathyroidism.
    Franceschini N; Joy MS; Kshirsagar A
    Expert Opin Investig Drugs; 2003 Aug; 12(8):1413-21. PubMed ID: 12882626
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can cinacalcet replace parathyroid intervention in severe secondary hyperparathyroidism?
    Kakuta T; Tanaka R; Kanai G; Sawaya A; Hirukawa T; Sato A; Saito A
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S20-7. PubMed ID: 19765255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical experience with cinacalcet HCl.
    Ureña Torres P
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V27-33. PubMed ID: 15284357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients.
    Serra AL; Savoca R; Huber AR; Hepp U; Delsignore A; Hersberger M; Wüthrich RP
    Nephrol Dial Transplant; 2007 Feb; 22(2):577-83. PubMed ID: 17005527
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical utility of calcimimetics targeting the extracellular calcium-sensing receptor (CaSR).
    Brown EM
    Biochem Pharmacol; 2010 Aug; 80(3):297-307. PubMed ID: 20382129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.
    Chertow GM; Blumenthal S; Turner S; Roppolo M; Stern L; Chi EM; Reed J;
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):305-12. PubMed ID: 17699221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment with cinacalcet of secondary hyperparathyroidism after renal transplantation.
    Gómez Marqués G; Obrador Mulet A; Vilar Gimeno A; Pascual Felip MJ; Alarcón Zurita A; Molina Guasch M; Uriol Rivera M; Munar Vila MA; Losada González P
    Transplant Proc; 2009; 41(6):2139-43. PubMed ID: 19715856
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calcium-sensing receptor expression and parathyroid hormone secretion in hyperplastic parathyroid glands from humans.
    Cañadillas S; Canalejo A; Santamaría R; Rodríguez ME; Estepa JC; Martín-Malo A; Bravo J; Ramos B; Aguilera-Tejero E; Rodríguez M; Almadén Y
    J Am Soc Nephrol; 2005 Jul; 16(7):2190-7. PubMed ID: 15888568
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.